Statin-induced insulin resistance through inflammasome activation: Sailing between scylla and charybdis

Diabetes

Volumn 63, Issue 11, 2014, Pages 3569-3571

  Mitchell, Patricia ^a   Marette, André ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CRYOPYRIN; FLUINDOSTATIN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; ROSUVASTATIN; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; INSULIN RESISTANCE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN INDUCTION; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; ANIMAL; DRUG EFFECTS; MALE; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CARRIER PROTEINS; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INFLAMMASOMES; MALE;

EID: 84908651413     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1059     Document Type: Note

References (22)

1. Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681
2. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]. Lancet 2010;375:2215-2222
3. Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125
4. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742
5. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-571
6. Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: Evidence from a large population-based cohort study. Diabetes Care 2014;37: 2225-2232
7. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-152
8. Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood) 2012;31:2276-2285
9. Park ZH, Juska A, Dyakov D, Patel RV. Statin-associated incident diabetes: a literature review. Consult Pharm 2014;29:317-334
10. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-445
11. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
12. Schertzer JD, Tamrakar AK, Magalhães JG, et al. NOD1 activators link innate immunity to insulin resistance. Diabetes 2011;60:2206-2215
13. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17:179-188
14. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010;327:296-300
15. Esser N, L'homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013;56:2487-2497
16. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013;62: 194-204
17. Henriksbo BD, Lau TC, Cavallari JF, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014;63:3742-3747
18. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol 2010;11:897-904
19. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11: 136-140
20. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279-288
21. Satoh M, Tabuchi T, Itoh T, Nakamura M. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin Sci (Lond) 2014;126:233-241
22. Yan Y, Jiang W, Spinetti T, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013;38:1154-1163